Omeros | OMER - Gross Profit On Sales


Omeros reported $-33.16M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Adma Biologics USD 80.75M 8.07M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Cytokinetics USD 23.03M 3.84M Jun/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Immunic 0 0 Mar/2025
Insmed USD 356.19M 99.73M Jun/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
MacroGenics USD 11.24M 19.87M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 133.91M 7.27M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Rockwell Medical USD 4.55M 1.49M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
United Therapeutics USD 683.8M 35.7M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026